Effects of an angiotensin-converting enzyme inhibitor and a β-blocker on cerebral arterioles in rats

被引:51
|
作者
Chillon, JM
Baumbach, GL
机构
[1] Univ Iowa, Coll Med, Dept Pathol, Med Labs 100, Iowa City, IA 52242 USA
[2] Univ Iowa, Ctr Cardiovasc, Iowa City, IA 52242 USA
关键词
hypertension; chronic; vascular remodeling; angiotensin; hypertrophy; vascular;
D O I
10.1161/01.HYP.33.3.856
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
We examined the effects of an angiotensin-converting enzyme inhibitor, perindopril, and a beta-blocker, propranolol, on cerebral arterioles in stroke-prone spontaneously hypertensive rats (SHRSP). The structure and mechanics of cerebral arterioles were examined in untreated Wistar-Kyoto rats (WKY) and SHRSP that were untreated or treated for 3 months with a high (2 mg/kg per day) or a low (0.3 mg/kg per day) dose of perindopril or propranolol (250 mg/kg per day) alone or in combination with the low dose of perindopril. We measured pressure, external diameter, and cross-sectional area of the vessel wall (CSA) in maximally dilated (with EDTA) cerebral arterioles. Treatment of SHRSP with the high dose of perindopril or the combination of propranolol and the low dose of perindopril normalized cerebral arteriolar mean pressure (50+/-1 [mean+/-SEM] and 43+/-2 mm Hg vs 50+/-1 mm Hg in WKY and 94+/-3 mm Hg in untreated SHRSP; P<0.05), pulse pressure (15+/-1 and 16+/-1 mm Hg vs 13+/-1 mm Hg in WKY and 35+/-1 mm Hg in untreated SHRSP; P<0.05), and CSA (1103+/-53 and 1099+/-51 mu m(2), respectively, vs 1057+/-49 mu m(2) in WKY and 1281+/-67 mu m(2) in untreated SHRSP; P<0.05). In contrast, treatment of SHRSP with the law dose of perindopril or propranolol alone did not normalize arteriolar pulse pressure (24+/-1 and 21+/-1 mm Hg) and failed to prevent increases in CSA (1282+/-77 and 1267+/-93 mu m(2)). Treatment with either dose of perindopril or the combination of propranolol and perindopril significantly increased external diameter in cerebral arterioles of SHRSP (99+/-3, 103+/-2, and 98+/-3 mu m vs 87+/-2 mu m in untreated SHRSP; P<0.05), whereas propranolol alone did not (91+/-3 mu m; P>0.05). These findings suggest that effects of angiotensin-converting enzyme inhibitors on cerebral arteriolar hypertrophy in SHRSP map depend primarily on their effects on arterial pressure, particularly pulse pressure, whereas their effects on cerebral arteriolar remodeling (defined as a reduction in external diameter) may be pressure independent.
引用
收藏
页码:856 / 861
页数:6
相关论文
共 50 条
  • [1] Effects of an angiotensin-converting enzyme inhibitor and a β-blocker on cerebral arteriolar dilatation in hypertensive rats
    Chillon, JM
    Baumbach, GL
    HYPERTENSION, 2001, 37 (06) : 1388 - 1393
  • [2] Effects of suboptimal doses of the AT1 receptor blocker, telmisartan, with the angiotensin-converting enzyme inhibitor, ramipril, on cerebral arterioles in spontaneously hypertensive rat
    Dupuis, Francois
    Vincent, Jean-Martin
    Liminana, Patrick
    Chillon, Jean-Marc
    Capdeville-Atkinson, Christine
    Atkinson, Jeffrey
    JOURNAL OF HYPERTENSION, 2010, 28 (07) : 1566 - 1573
  • [3] Comparative effects of the angiotensin II receptor blocker, telmisartan, and the angiotensin-converting enzyme inhibitor, ramipril, on cerebrovascular structure in spontaneously hypertensive rats
    Dupuis, F
    Atkinson, J
    Limiñana, P
    Chillon, JM
    JOURNAL OF HYPERTENSION, 2005, 23 (05) : 1061 - 1066
  • [4] Effects of enalapril on the expression of cardiac angiotensin-converting enzyme and angiotensin-converting enzyme 2 in spontaneously hypertensive rats
    Yang, Zhen
    Yu, Xin
    Cheng, Li
    Miao, Li-yan
    Li, Hong-xia
    Han, Lian-hua
    Jiang, Wen-ping
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2013, 106 (04) : 196 - 201
  • [5] Therapeutic perspective: starting an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in a diabetic patient
    Jarred, Ghassan
    Kennedy, R. Lee
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2010, 1 (01) : 23 - 28
  • [6] Effectiveness of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker on atrial natriuretic peptide
    Sata, N
    Tanaka, Y
    Suzuki, S
    Kamimura, R
    Mifune, H
    Nakamura, K
    Miyahara, K
    Arima, T
    CIRCULATION JOURNAL, 2003, 67 (12) : 1053 - 1058
  • [7] Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans
    Laurent, S
    Boutouyrie, P
    Azizi, M
    Marie, C
    Gros, C
    Schwartz, JC
    Lecomte, JM
    Bralet, J
    HYPERTENSION, 2000, 35 (05) : 1148 - 1153
  • [8] Murine Recombinant Angiotensin-Converting Enzyme 2 Effect on Angiotensin II-Dependent Hypertension and Distinctive Angiotensin-Converting Enzyme 2 Inhibitor Characteristics on Rodent and Human Angiotensin-Converting Enzyme 2
    Ye, Minghao
    Wysocki, Jan
    Gonzalez-Pacheco, Francisco R.
    Salem, Mahmoud
    Evora, Karla
    Garcia-Halpin, Laura
    Poglitsch, Marko
    Schuster, Manfred
    Batlle, Daniel
    HYPERTENSION, 2012, 60 (03) : 730 - +
  • [9] EFFECTS OF CHRONIC ADMINISTRATION OF AN ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR ON ANGIOTENSIN-CONVERTING ENZYME-ACTIVITY IN THE PARS RECTA OF RABBITS
    PRADDAUDE, F
    TRANVAN, T
    MARCHETTI, J
    GIROLAMI, JP
    ADER, JL
    CLINICAL SCIENCE, 1990, 79 (01) : 29 - 35
  • [10] Efficacy of combination therapy with angiotensin-converting enzyme inhibitor and calcium channel blocker in hypertension
    Redon, Josep
    Trenkwalder, Peter R. A.
    Barrios, Vivencio
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (02) : 155 - 164